Oncotelic Therapeutics, Inc. (OTLC)
OTCMKTS · Delayed Price · Currency is USD
0.0513
-0.0032 (-5.79%)
Aug 1, 2025, 2:59 PM EDT

CTI BioPharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202018 - 2020
Period Ending
Aug '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2020
211415186319
Upgrade
Market Cap Growth
97.34%-6.64%-13.25%-71.94%225.64%34.48%
Upgrade
Enterprise Value
332627277021
Upgrade
Last Close Price
0.050.040.040.040.170.21
Upgrade
PE Ratio
---3.45--
Upgrade
PS Ratio
--218.13--11.06
Upgrade
PB Ratio
2.911.911.320.927.691.54
Upgrade
P/TBV Ratio
4.002.612.492.40--
Upgrade
EV/Sales Ratio
--384.58--12.14
Upgrade
Debt / Equity Ratio
1.851.751.080.591.100.37
Upgrade
Asset Turnover
--0.00--0.07
Upgrade
Quick Ratio
0.010.010.010.020.040.04
Upgrade
Current Ratio
0.010.010.020.020.040.06
Upgrade
Return on Equity (ROE)
-50.65%-50.08%-53.28%34.20%-101.92%-67.88%
Upgrade
Return on Assets (ROA)
-0.68%-0.83%-1.07%-11.74%-24.13%-20.02%
Upgrade
Return on Capital (ROIC)
-0.87%-1.05%-1.29%-14.73%-33.27%-27.09%
Upgrade
Earnings Yield
-21.09%-31.74%-51.76%28.95%-14.97%-49.34%
Upgrade
Buyback Yield / Dilution
-5.33%-5.29%16.01%-50.89%-244.02%-46.94%
Upgrade
Updated Nov 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.